Companies / Santa Cruz Biotechnology / ERK 2 (D-2) Alexa Fluor® 647
Santa Cruz Biotechnology

ERK 2 (D-2) Alexa Fluor® 647 | Santa Cruz Biotechnology

mouse monoclonal IgG2b; ERK 2 Antibody (D-2) is an IgG2b κ mouse monoclonal ERK 2 antibody (also designated ERK 2 antibody or MAPK1 antibody) that detects ERK 2 p42 of mouse, rat and human origin by WB, IP, IF, IHC(P), FCM and ELISA. ERK 2 Antibody (D-2) is available as the non-conjugated anti-ERK 2 antibody form, as well as multiple conjugated forms of anti-ERK 2 antibody, including agarose, HRP, PE, FITC and multiple Alexa Fluor® conjugates. Mitogen-activated protein kinase (MAPK) signaling pathways involve two closely related MAP kinases, known as extracellular-signal-related kinase 1 (ERK 1, p44) and 2 (ERK 2, p42). Growth factors, steroid hormones, G protein-coupled receptor ligands, and neurotransmitters can initiate MAPK signaling pathways. Activation of ERK1 and ERK2 requires phosphorylation by upstream kinases such as MAP kinase kinase (MEK), MEK kinase and Raf-1. ERK1 and ERK2 phosphorylation can occur at specific tyrosine and threonine sites mapping within consensus motifs that include the Threonine-Glutamate-Tyrosine motif. ERK activation leads to dimerization with other ERKs and subsequent localization to the nucleus. Active ERK dimers phosphorylate serine and threonine residues on nuclear proteins and influence a host of responses that include proliferation, differentiation, transcription regulation and development. The human ERK2 gene maps to chromosome 22q11.21 and encodes a 360-amino acid protein.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.